« Back
Home /
CX-5461

CX-5461

Item no.	HY-13323-10mg
Manufacturer	MedChem Express
CASRN	1138549-36-6
Amount	10 mg
Quantity options	100 mg 10 mg 1 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Lymphatic System Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.49
Formula	C27H27N7O2S
Citations	Acta Biomater. 2018 Oct 1;79:317-330. Am J Pathol. 2021 Mar 8;S0002-9440(21)00084-5. Biochim Biophys Acta. 2017 Dec 8;1862(3):615-629. Biochimie. 2022 Apr 20;199:81-91. Biomed Pharmacother. 2021 Jan;133:110906. bioRxiv. 2021 Dec. bioRxiv. 2024 November 28. bioRxiv. 2024 October 13. bioRxiv. 2024 Sep 29:2024.09.28.615444. bioRxiv. 2025 January 21. Cancer Res. 2022 Jan 12;canres.1707.2021. Cell Commun Signal. 2022 Sep 5;20(1):96. Cell Death Dis. 2024 Mar 29;15(3):236. Cell. 2024 Mar 28;187(7):1701-1718.e28. Clin Cancer Res. 2017 Nov 1;23(21):6529-6540. Development. 2024 Sep 26:dev.202875. EMBO Mol Med. 2021 Mar 5;13(3):e12834. FASEB J. 2020 Jun;34(6):8283-8295. Free Radic Biol Med. 2024 Aug 5:S0891-5849(24)00589-6. Harvard Medical School LINCS LIBRARY Invest New Drugs. 2021 Mar 12. J Cell Biol. 2023 Jan 2;222(1):e202202110. J Extracell Vesicles. 2023 Oct;12(10):e12361. J Transl Med. 2024 Dec 25;22(1):1147. Life Sci Alliance. 2019 Feb 26;2(2):e201800222. Matrix Biol. 2024 Oct 5:S0945-053X(24)00124-0. Mol Cancer Ther. 2018 Jun;17(6):1177-1186. Mol Cancer. 2024 Dec 20;23(1):275. Molecular Therapy Oncology. 2024 Feb 7. Molecules. 2019 Dec 4;24(24):4445. Nat Cell Biol. 2022 Jul;24(7):1154-1164. Nat Commun. 2017 Sep 25;8(1):693. Nat Commun. 2022 Jun 28;13(1):3706. Nat Commun. 2024 Feb 9;15(1):1231. Nat Commun. 2025 Jan 2;16(1):121. Nat Commun. 2025 Jan 4;16(1):390. Nucleic Acids Res. 2022 May 6;50(8):4574-4600. Oncotarget. 2017 Oct 29;8(57):96536-96552. Open Biol. 2025 Feb;15(2):240183. Patent. US20190169215A1 Utrecht University. 2023 Feb. bioRxiv. 2023 Jan 31. Sci Adv. 2023 Sep;9(35):eadg7125. [1]Drygin D et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011 Feb 15;71(4):1418-30. [2]Bywater MJ, et al. Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell. 2012 Jul 10;22(1):51-65.
Smiles	CC1=NC=C(CNC(C2=C3N(C4=NC(N5CCN(CCC5)C)=CC=C4C2=O)C6=C(S3)C=CC=C6)=O)N=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1138549-36-6
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	DNA/RNA Synthesis
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	513.61
Product Description	CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	50 mM Sodium phosphate (pH 3.5) : 10 mg/mL (ultrasonic)\|DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : 55.56 mg/mL (ultrasonic; adjust pH to 2 with HCl)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13323-10mg-safety-datasheet.pdf